Cardiac angiosarcoma: an unexpected diagnosis

Milton Roberto Furst Crenitte a, Mariana Domingues Galvão b, Fabiola Del Carlo Bernardi c, Leonardo Gomes da Fonseca d

Crenitte MRF, Galvão MD, Bernardi FDC, Fonseca LG. Cardiac angiosarcoma: an unexpected diagnosis. Autopsy Case Rep [Internet]. 2014;4(3):53-8. http://dx.doi.org/10.4322/acr.2014.029

ABSTRACT

Cardiac angiosarcoma is a rare entity. The incidence through autopsy findings ranges between 0.001% and 0.03%. The disease usually presents with non-specific symptoms, although asymptomatic cases are frequent; therefore, diagnosis is unexpected and consequently delayed. The authors report the case of a middle-aged man with a recent onset cough and dyspnea. He sought medical care several times without receiving a definite diagnosis until a plain chest radiography was taken showing a mediastinal enlargement, which was the reason why he was hospitalized for clinical investigation. During the diagnostic workup, an echodopplercardiogram and a thoracic computed tomography were performed, showing a heterogeneous soft-tissue mass infiltrating the pericardium and the anterior atrial wall. Multiple and scattered pulmonary nodules were also present. A pulmonary nodule was biopsied, which revealed an angiosarcoma. The clinical features added to the radiological and histological findings permitted the diagnosis of right atrial angiosarcoma. The authors highlight the unexpected pattern in the presentation of cardiac tumors.

Keywords
Hemangiosarcoma; Heart Neoplasms, Incidental Findings.

CASE REPORT

A 63-year-old male patient sought the medical facility complaining of recent productive cough and dyspnea. His past medical history included pulmonary tuberculosis, which was treated few years before, and smoking of 15 packs/year. He had sought medical care several times during the prior 2 months, but was always treated with symptomatic medication until a plain chest radiography was taken, which showed mild mediastinal enlargement and a bulging on the right atrium contour (Figure 1). This was the reason for the hospital admission and clinical investigation.

The initial physical examination revealed an afebrile patient, who presented normal hemodynamic parameters and no peripheral edema. Lung examination was normal, and cardiac auscultation revealed an ejection murmur. Raised jugular venous pressure and hepatomegaly were also observed. The remaining examination was normal and the initial laboratory workup was unremarkable.

The echodopplercardiogram showed pericardium thickening with mild effusion and a left ventricular ejection fraction of 60%. Thoracic computed
tomography (CT) showed a mass with soft tissue attenuation infiltrating the pericardium and the anterior wall of the right atrium (Figure 2) and multiple, bilateral, scattered, solid pulmonary nodules measuring up to 2.6 cm.

The magnetic resonance imaging (MRI) also showed a mass with heterogeneous distinction diffusely involving the pericardium, with compression/invasion of the right ventricle’s outflow tract, pulmonary artery and superior vena cava (Figures 3 and 4).

The pericardium was biopsied, but the histological examination did not reveal evidence of malignancy. A pulmonary nodule was subsequently biopsied, which showed a mesenchymal malignancy represented by sinusoidal vascular channels filled with red blood cells and lined with atypical endothelial cells (Figure 5A). The immunohistochemical profile showed positivity for CD31, CD34 (Figure 5B), while Desmin and S100 Protein were negative, rendering the diagnosis of angiosarcoma. Adding the radiological and clinical findings to the histological clues, the final diagnosis was metastatic angiosarcoma primary to the right atrium.

The patient received chemotherapy with doxorubicin 25 mg/m² from day 1 to 3, and ifosfamide 2000 mg/m² from day 1 to 5 every 21 days. After two cycles, CT showed reduction in the size of the pulmonary nodules (from a maximum of 2.6 cm down to a maximum of 1.8 cm). Before the third cycle of chemotherapy, the patient was admitted to the emergency department with a pulmonary infection. Despite intensive care, he developed refractory septic shock and died after 24 days.

**DISCUSSION**

Primary cardiac tumors are extremely rare. The incidence of these tumors in autopsy findings ranges from 0.001% to 0.03%. About 80% of the tumors are benign, and are represented...
Figure 3. Cardiac MRI. A - T2 weighted image - (short axis double sequences) Heterogeneous mass with right atrium isosignal in the pericardial cavity (arrow) and a small area with slightly increased signal that can represent pericardial effusion (arrowhead); B - T2 weighted image - (after administration of gadolinium) Heterogeneous enhancement of the mass (arrow), consistent with tumor.

Figure 4. Cardiac MRI (T2 weighted images) showing heterogeneous hyperintense mass (arrows) in A, B, C - Left ventricle's outlet, four-chamber view, and short-axis view, respectively.

Figure 5. Photomicrography of the biopsy of the pulmonary nodule. A - Sinusoidal vascular channels lined by atypical endothelial cells and areas of necrosis (arrow) (H&E, 400X); B - Cytoplasmic staining positive to vascular marker: CD34 (x100).
mostly by atrial myxomas. The remaining cases are malignant neoplasias represented mostly by cardiac angiosarcomas with a specific type of differentiation, however undifferentiated pleomorphic sarcomas are more common.²⁻⁶

Angiosarcomas represent up to 30% of all cardiac malignancies.³ Although they can arise from any heart chamber, in the majority of cases they are found in the right atrium.⁷ Male and middle-aged patients, like the patient reported herein, are predominantly affected.³,⁸

The disease usually progresses without symptoms until the tumor burden compromises hemodynamic stability, and/or causes systemic derangement, or regional metastases arise.⁷ Symptoms may be nonspecific, such as a mild increase in temperature, weight loss, exhaustion, muscle pain, night sweats, and cough.⁸ Nonetheless, depending on the site of the tumor and its extension to the neighboring tissue infiltration, characteristic cardiac symptoms or signs will be present; such as angina, dyspnea, arrhythmias, stroke, and sudden cardiac arrest.⁷,⁹ Pericardial effusion and cardiac tamponade are frequent.¹⁰

Because of the non-specific presenting symptoms, and the unfamiliarity of most physicians with this entity, the diagnosis is overlooked and consequently often delayed.¹¹ Besides the diagnostic delay, the aggressive behavior characterized by the early spreading of the tumor and rapid local infiltration contribute to the poor prognosis.¹² Most patients die within a few months after diagnosis.¹³

Some patients are incidentally diagnosed when submitted to thoracic imaging for other purpose. Non-invasive cardiac imaging greatly contributes to the radiologic evaluation of these tumors. The disease usually progresses without symptoms until the tumor burden compromises hemodynamic stability, and/or causes systemic derangement, or regional metastases arise.⁷ Symptoms may be nonspecific, such as a mild increase in temperature, weight loss, exhaustion, muscle pain, night sweats, and cough.⁸ Nonetheless, depending on the site of the tumor and its extension to the neighboring tissue infiltration, characteristic cardiac symptoms or signs will be present; such as angina, dyspnea, arrhythmias, stroke, and sudden cardiac arrest.⁷,⁹ Pericardial effusion and cardiac tamponade are frequent.¹⁰

Because of the non-specific presenting symptoms, and the unfamiliarity of most physicians with this entity, the diagnosis is overlooked and consequently often delayed.¹¹ Besides the diagnostic delay, the aggressive behavior characterized by the early spreading of the tumor and rapid local infiltration contribute to the poor prognosis.¹² Most patients die within a few months after diagnosis.¹³

Some patients are incidentally diagnosed when submitted to thoracic imaging for other purpose. Non-invasive cardiac imaging greatly contributes to the radiologic evaluation of these tumors. Intracardiac thrombus or vegetation constitute the main differential diagnoses; thus, the first step during diagnostic evaluation is ruling out these other diagnostic possibilities,⁷ usually by echocardiography.¹⁴ In this setting, transesophageal echocardiogram shows 97% of sensitivity in diagnosing cardiac masses.¹⁵ In cases of an inconclusive cardiac tumor diagnosis by the former examination, CT or magnetic resonance imaging (MRI) can be utilized.⁷

MRI allows better overall soft-tissue characterization and is more versatile than the CT when it can provide some functional information, such as flow direction and flow velocity in large vessels.¹⁶ However, CT is more readily available in most centers, been then a modality of choice for evaluating abnormalities intrinsic to the myocardium.

Optimal images are important when preceding surgical resections, but in the present case performing both modalities in parallel did not alter the clinical reasoning.

There are two main morphologic types described in angiosarcoma. The first is a well-defined mass protruding into one of the cardiac chambers, usually the right atrium.¹⁷,¹⁸ CT often shows a low-attenuating right atrium mass, which may be irregular or nodular. The contrast medium enhancement is heterogeneous.¹⁶ The second morphologic type is a diffusely infiltrative mass extending along the pericardium that may appear on CT as pericardial effusion or thickening.¹⁶,¹⁸

Because of the tumor propensity to bleeding and the presence of necrosis, heterogeneous signal intensity on CT and MRI is typical. On T1-weighted fast spin-echo (FSE) sequences, tumors are typically low-signal, and T2-weighted FSE images typically show an increased signal. Areas of increased signal intensity on T1-weighted images (focal or peripheral) are thought to represent blood products and because of their high vascularity, strong signal enhancement is seen after gadolinium injection.¹⁸,¹⁹

¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG PET/CT) is another tool that can be helpful in the determination of the tumor’s malignant potential as well as tumoral staging.²⁰ However, histological diagnosis still remains the diagnostic gold standard.²¹

Unfortunately, at the time of diagnosis, metastases are frequently present and are mostly disseminated to the lungs, although lymph nodes, bone, adrenal glands, liver, and spleen may also be involved.²²

An interdisciplinary approach is crucial in the management of cardiac tumors. Considering the rarity of this malignancy, there is no recommended standard therapy and evidence is based on single case reports and retrospective series.

Surgical resection plays an important role, not only with a curative goal, but also to restore normal hemodynamics. Complete resection is the treatment
of choice, although many patients show progression of the disease even after resection.1

Adjuvant chemotherapy and radiotherapy have been described in case series, but no randomized trials have been conducted. Therefore, the benefit of these modalities in reducing local and distant recurrences after complete resection is uncertain.

Llombart-Cussac et al.23 reported a series with 15 patients with localized cardiac sarcomas (6 of whom had angiosarcomas) who were treated with adjuvant doxorubicin-containing regimen within 6 weeks after a complete resection. The overall median time to recurrence was 10 months. For those patients with angiosarcoma, this median time was 3 months. Median survival time for angiosarcoma was 7 months.23 However, combined modality and adjuvant therapy can provide long-term disease control.24-26

Heart transplantation has been considered as a final treatment option in individual cases, especially in young patients with no other treatment option,27 but the reported outcomes are discouraging.28

In the metastatic scenario, chemotherapy may provide symptom relief, improve quality of life, and increase survival time. Prospective clinical trials on advanced soft tissue sarcoma researching clinical benefit with doxorubicin-based chemotherapy did not individualize outcomes of patients with angiosarcoma. However, many reports suggest a substantial rate of response with doxorubicin, doxorubicin plus ifosfamide, vincristine and taxanes.29-31 Recent phase II trials, with target therapies sorafenib and bevacizumab in the treatment of advanced angiosarcoma, have yielded promising results on the efficacy of these agents.32

In the present case, diagnosis was not suspected on clinical grounds. The suspicion was raised after plain thoracic radiography and henceforth was enlightened with other imaging techniques. Angiosarcoma was confirmed with the immunohistochemical panel of a pulmonary nodule biopsy. Cardiac tumors, although rare, are somewhat easily diagnosed with the additional of imaging methods. Obtaining histological samples may be troublesome. When metastatic disease is the presenting form, pathological documentation may be more easily accessed. Awareness of the entity and the knowledge of its clinical features are the cornerstone to decreasing the delay in diagnosis.

REFERENCES

1. Centofanti P, Di Rosa E, Deorsola L, et al. Primary cardiac tumors: early and late results of surgical treatment in 91 patients. Ann Thorac Surg. 1999;68(4):1236-41. http://dx.doi.org/10.1016/S0003-4975(99)00700-6. PMid:10543485

2. Strecer T, Rösch J, Weyand M, Agaimy A. Primary and metastatic cardiac tumors: imaging characteristics, surgical treatment, and histopathological spectrum: a 10-year-experience at a German heart center. Cardiovasc Pathol. 2012;21(5):436-43. http://dx.doi.org/10.1016/j.carpath.2011.12.004. PMid:22300501

3. Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 1996;77(1):107. http://dx.doi.org/10.1016/S0002-9149(97)89149-7. PMid:8540447

4. Shapiro LM. Cardiac tumours: diagnosis and management. Heart. 2001;85(2):218-22. http://dx.doi.org/10.1136/heart.85.2.218. PMid:11156679

5. Burke AP, Tazelaar H, Butany JW, et al. Cardiac sarcomas. In: Travis W, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, thymus, pleura and heart. Lyon: ARC Press; 2004. p. 273-81

6. Burke AP, Tavora F. Sarcomas of the heart and great vessels. In: Burke AP, Tavora F. Practical cardiovascular pathology. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 398-406

7. Hoffmeier A, Sindermann JR, Scheld HH, Martens S. Cardiac tumors—diagnosis and surgical treatment. Dtsch Arztebl Int. 2014;111(12):205-11. PMid:24717305

8. Neragi-Miandoab S, Kim J, Vlahakes GJ. Malignant tumours of the heart: a review of tumour type, diagnosis and therapy. Clin Oncol (R Coll Radiol). 2007;19(10):748-56. http://dx.doi.org/10.1016/j.clon.2007.06.009. PMid:17693068

9. Strotmann J. Cardiac tumors—clinical symptoms, diagnostic approaches, and therapeutic aspects. Med Klin (Munich). 2008;103(3):175-80. PMid:18344068

10. Antonuzzo L, Rotella V, Mazzoni F, et al. Primary cardiac angiosarcoma: a fatal disease. Case Rep Med. 2009;2009:1-4. http://dx.doi.org/10.1155/2009/591512. PMid:19724650

11. Bellitti R, Buonocore M, De Rosa N, Covino FE, Casale B, Santé P. Primary cardiac angiosarcoma in a 25-year-old man: excision, adjuvant chemotherapy, and multikinase inhibitor therapy. Tex Heart Inst J. 2013;40(2):186-8. PMid:23678219

12. Glancy DL, Morales JB Jr, Roberts WC. Angiosarcoma of the heart. Am J Cardiol. 1968;21(3):413-9. http://dx.doi.org/10.1016/0002-9149(68)90144-6. PMid:4230097

13. Hoffmeier A, Schmid C, Deiters S, et al. Neoplastic heart disease — the Muenster experience with 108 patients. Thorac Cardiovasc Surg. 2005;53(1):1-8. http://dx.doi.org/10.1055/s-2004-830389. PMid:15692911
14. Alam M, Rosman HS, Grullon C. Transesophageal echocardiography in evaluation of atrial masses. Angiology. 1995;46(2):123-8. http://dx.doi.org/10.1177/000331979504600205. PMid:7702196

15. Riles E, Gupta S, Wang DD, Tobin K. Primary cardiac angiosarcoma: A diagnostic challenge in a young man with recurrent pericardial effusions. Exp Clin Cardiol. 2012;17(1):39-42. PMid:23204900.

16. Araoz PA, Eklund HE, Welch TJ, Breen JF. CT and MR imaging of primary cardiac malignancies. Radiographics. 1999;19(6):1421-34. http://dx.doi.org/10.1148/radiographics.19.6.g99no031421. PMid:10555666.

17. Iglézias JCR, Velloso LGC, Dallan LA, Benvenuti LA, Verginelli G, Stolf NAG. Angiossarcoma de átrio direito. Rev Bras Cir Cardiovasc. 2000;15(2):186-91. http://dx.doi.org/10.1590/S0102-76382000000200013.

18. Janigan DT, Husain A, Robinson NA. Cardiac angiosarcomas. A review and a case report. Cancer. 1986;57(4):852-9. http://dx.doi.org/10.1002/1097-0142(19860215)57:4<852::AID-CNCR2820570428>3.0.CO;2-S. PMid:3510706.

19. O’Donnell DH, Abbara S, Chaithiraphan V, et al. Cardiac tumors: optimal cardiac MR sequences and spectrum of imaging appearances. AJR Am J Roentgenol. 2009;193(2):377-87. http://dx.doi.org/10.2214/AJR.08.1895. PMid:19620434.

20. Sibille L, Ilonca D, Oziol E, et al. FDG PET/CT in aortic angiosarcoma. Clin Nucl Med. 2010;35(2):134-7. http://dx.doi.org/10.1097/RLU.0b013e3181e3181c7c0a2. PMid:20904070.

21. Barreiro M, Renilla A, Jimenez JM, et al. Primary cardiac tumors: 32 years of experience from a Spanish tertiary surgical center. Cardiovasc Pathol. 2013;22(6):424-7. http://dx.doi.org/10.1016/j.carpath.2013.04.006. PMid:23727543.

22. Silver MD, Gottlieb AI, Schoen FJ. Cardiovascular pathology. 3rd ed. Philadelphia: Churchill Livingstone; 2001. p. 399-598.

23. Llombart-Cussac A, Pivot X, Contesso G, et al. Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer. 1998;78(12):1624-8. http://dx.doi.org/10.1038/bjc.1998.733. PMid:9862574.

24. Nakamichi T, Fukuda T, Suzuki T, Kaneko T, Morikawa Y. Primary cardiac angiosarcoma: 53 months’ survival after multidisciplinary therapy. Ann Thorac Surg. 1997;63(4):1160-1. http://dx.doi.org/10.1016/S0003-4975(96)01395-1. PMid:9124928.

25. Kakizaki S, Takagi H, Hosaka Y. Cardiac angiosarcoma responding to multidisciplinary treatment. Int J Cardiol. 1997;62(3):273-5. http://dx.doi.org/10.1016/S0167-5273(97)00259-3. PMid:9476688.

26. Baay P, Karwande SV, Kushner JP, Olsen S, Renlund DG. Successful treatment of a cardiac angiosarcoma with combined modality therapy. J Heart Lung Transplant. 1994;13(5):923-5. PMid:7803440.

27. Überfuhr P, Meiser B, Fuchs A, et al. Heart transplantation: an approach to treating primary cardiac sarcoma? J Heart Lung Transplant. 2002;21(10):1135-9. http://dx.doi.org/10.1016/S1053-2498(02)00409-6. PMid:12398881.

28. Look Hong NJ, Pandalai PK, Hornick JL, et al. Cardiac angiosarcoma management and outcomes: 20-year single-institution experience. Ann Surg Oncol. 2012;19(8):2707-15. http://dx.doi.org/10.1245/s10434-012-2334-2. PMid:22476752.

29. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030-6. http://dx.doi.org/10.1093/annonc/mdm381. PMid:17974557.

30. Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol. 1998;22(6):683-97. http://dx.doi.org/10.1097/00000478-199806000-00005. PMid:9630175.

31. Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86(10):2034-7. http://dx.doi.org/10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR2>3.0.CO;2-P. PMid:10570428.

32. Penel N, Marréaud S, Robin YM, Hohenberger P. Angiosarcoma: state of the art and perspectives. Crit Rev Oncol Hematol. 2011;80(2):257-63. http://dx.doi.org/10.1016/j.critrevonc.2010.10.007. PMid:21055965.

Conflict of interest: None

Submitted on: July 17, 2014
Accepted on: September 2, 2014

Correspondence
Divisão de Clínica Médica
Hospital Universitário da Universidade de São Paulo
Av. Prof. Lineu Prestes, 2565 – Cidade Universitária – São Paulo/SP – Brazil
CEP 05508-000
Phone +55 (11) 3091-9200
E-mail mi.rfc@uol.com.br